Clinical Trial Details
| Trial ID: | L4857 |
| Source ID: | NCT00097955 |
| Associated Drug: | Aliskiren |
| Title: | Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetic Nephropathy |
| Interventions: | DRUG: aliskiren |
| Outcome Measures: | Primary: Change from baseline in urinary albumin creatinine ratio after 24 weeks | Secondary: Equal/more than 50% reduction from baseline in urinary albumin creatinine ratio after 24 weeks|Change from baseline in urinary albumin excretion rate after 24 weeks |
| Sponsor/Collaborators: | Sponsor: Novartis Pharmaceuticals |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 496 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: OTHER |
| Start Date: | 2004-10 |
| Completion Date: | 2007-04 |
| Results First Posted: | |
| Last Update Posted: | 2017-05-17 |
| Locations: | Novartis Pharmaceuticals, East Hanover, New Jersey, 07936, United States|Investigative Site, Quebec, Canada|Investigative Site, Hillerod, Denmark|Investigative Site, Paris, France|Investigative Centers, Germany|Investigative Site, Athens, Greece|Investigative Site, Rome, Italy|Investigative Site, Rotterdam, Netherlands|Investigative Site, Bucharest, Romania|Investigative Site, Moscow, Russian Federation|Investigative Site, Madrid, Spain|Investigative Site, London, United Kingdom |
| URL: | https://clinicaltrials.gov/show/NCT00097955 |
